Shield Therapeutics (LON:STX) is making excellent progress having reported two sets of new supportive clinical data on its lead product Feraccru, a low dose oral iron capsule. Feraccru is being positioned as an alternative therapy for patients with iron deficiency (ID) and iron deficiency anaemia (
09 May 2019
Shield Therapeutics PLC Heading for a US approval decision
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Shield Therapeutics PLC Heading for a US approval decision
Shield Therapeutics Plc (STX:LON) | 1.5 0 (-0.3%) | Mkt Cap: 11.5m
- Published:
09 May 2019 -
Author:
Emma Ulker -
Pages:
6
Shield Therapeutics (LON:STX) is making excellent progress having reported two sets of new supportive clinical data on its lead product Feraccru, a low dose oral iron capsule. Feraccru is being positioned as an alternative therapy for patients with iron deficiency (ID) and iron deficiency anaemia (